Riding the coattails of CAR-T cancer therapies, scientists have begun to explore a spin-off: using similar immune cells to treat autoimmune diseases such as type 1 diabetes and prevent rejection of transplanted organs.
In CAR-T therapies, T cells are extracted from a patient’s blood, reprogrammed to attack cancer cells, and then re-infused into the bloodstream to carry out their new assignment.
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.
What's included?
- Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
- Subscriber-only networking events and panel discussions across the country
- Monthly subscriber-only live chats with our reporters and experts in the field
- Discounted tickets to industry events and early-bird access to industry reports
